Brought to you by 
GSK invests $20mm in XenoPort stock, with option to buy $20mm more
03 Dec 2012
Executive Summary
On the heels of terminating their five-year-old agreement for the restless legs syndrome product Horizant (gabapentin), GlaxoSmithKline PLC and XenoPort Inc. (neurological, musculoskeletal, and dermatological therapeutics) have decided to not completely sever ties. GSK has agreed to buy $20mm in XenoPort stock for approximately a 4.3% stake.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK invests $20mm in XenoPort stock, with option to buy $20mm more
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice